Literature DB >> 2811363

Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition.

P E Lønning1, D C Johannessen, T Thorsen, D Ekse.   

Abstract

Plasma levels of estrone and estrone sulfate were measured in 16 postmenopausal women with advanced breast cancer before and during chronic aminoglutethimide therapy. Aminoglutethimide caused a significant reduction in plasma estrone (mean 36%, P less than 0.025) and estrone sulfate (mean 65%, P less than 0.001). The estrone/estrone sulfate ratio was increased by a mean of 84% (P less than 0.0025). These results suggest that aminoglutethimide influences plasma estrone sulfate by mechanisms unrelated to aromatase inhibition. The findings in this study are consistent with previous results suggesting that aminoglutethimide treatment enhances the rate of estrone sulfate metabolism. This biochemical effect of aminoglutethimide treatment could be a contributory factor to the drugs mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2811363     DOI: 10.1016/0022-4731(89)90039-3

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  6 in total

1.  Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.

Authors:  P E Lønning; M Dowsett; A Jones; D Ekse; S Jacobs; F McNeil; D C Johannessen; T J Powles
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 2.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.

Authors:  B P Haynes; M Jarman; M Dowsett; A Mehta; P E Lønning; L J Griggs; A Jones; T Powles; R Stein; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.

Authors:  P E Lønning
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.

Authors:  D C Johannessen; H Adlercreutz; T Fotsis; P E Lønning
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

6.  The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.

Authors:  F A MacNeill; A L Jones; S Jacobs; P E Lønning; T J Powles; M Dowsett
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.